Amarin cardiovascular news
Amarin said the U.S. Patent and Trademark Office (PTO) issued a notice of allowance for Patent Application No. 13/610,247. The patent covers claims for Vascepa icosapent ethyl (formerly AMR101) to treat hypertriglyceridemia -- its approved indication. The application claims cover the use of Vascepa with and without other lipid lowering agents such as statins. According to the company, a similar application -- Patent Application No. 13/608,775 -- received a notice of allowance from the PTO in November.
In a Nov. 8 SEC filing, which was prior to the current notices, the company said it has two patents covering pharmaceutical composition of Vascepa in a capsule that expire in 2020 and 2030, respectively; one patent covering highly pure eicosapentaenoic acid, which expires in 2021; two additional patents covering the use of Vascepa, which expire in 2030; and notices of allowance from the PTO for three additional patent applications, which have terms that expire in 2030 and are related to the use of Vascepa and potentially competitive products. ...